טוען...
Belimumab is a promising third-line treatment option for refractory autoimmune hepatitis
BACKGROUND & AIMS: Autoimmune hepatitis (AIH) is a disease of unknown aetiology with a favourable response to immunosuppression. However, in the clinic, it appears that <50% of patients achieve complete response on standard treatment. Serum B cell-activating factor (BAFF) levels are elevated...
שמור ב:
| הוצא לאור ב: | JHEP Rep |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7340979/ https://ncbi.nlm.nih.gov/pubmed/32671332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jhepr.2020.100123 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|